The report “Recommendations for Expanding Regulatory Agility and Evidentiary Integrity in Developing Treatments for Rare Diseases” from the Reagan‑Udall Foundation for the FDA offers a forward‑looking vision for strengthening the role of patient‑relevant endpoints in rare disease drug development. Developed from a Roundtable discussion of leaders across medical research, patient advocacy, regulatory agencies, and industry, the report highlights practical strategies to make rare disease clinical development more efficient, more collaborative, and more patient‑centered.
Across four key areas—patient‑relevant endpoints, patient perspective and natural history data, evidentiary expectations and regulatory requirements, and cross‑stakeholder knowledge management—the group identified ten core challenges and developed twenty actionable recommendations. Together, these recommendations aim to move patient‑focused rare disease drug development from principle to practice, enabling faster progress and more meaningful outcomes for the rare disease community.
